Dynavax Technologies Company Insiders
| DVAX Stock | USD 13.82 0.20 1.47% |
Dynavax Technologies employs about 405 people. The company is managed by 18 executives with a total tenure of roughly 28 years, averaging almost 1.0 years of service per executive, having 22.5 employees per reported executive. Break down of Dynavax Technologies' management performance can provide insight into the company performance.
| Robert Janssen President Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs |
| Ryan Spencer President Interim Co-President Co-Principal Executive Officer |
Dynavax |
Dynavax Technologies' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Dynavax Technologies' future performance. Based on our forecasts, it is anticipated that Dynavax will maintain a workforce of slightly above 410 employees by April 2025.Dynavax Technologies Management Team Effectiveness
At this time, Dynavax Technologies' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.03 in 2025, whereas Return On Capital Employed is likely to drop (0) in 2025. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 21.4 M in 2025, whereas Other Assets are likely to drop slightly above 3 M in 2025. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to rise to about 140 M in 2025. Net Income Applicable To Common Shares is likely to rise to about 353.6 M in 2025
Dynavax Technologies Workforce Comparison
Dynavax Technologies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 11,320. Dynavax Technologies holds roughly 405 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01. Dynavax Technologies Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dynavax Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dynavax Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Dynavax Technologies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 1.0294 | 35 | 34 | 1,362,649 | 495,245 |
| 2024-06-01 | 9.0 | 18 | 2 | 237,856 | 7,500 |
| 2024-03-01 | 0.7714 | 27 | 35 | 948,942 | 814,538 |
| 2023-12-01 | 0.4615 | 6 | 13 | 106,770 | 213,540 |
| 2023-09-01 | 0.4706 | 8 | 17 | 106,118 | 1,712,236 |
| 2023-06-01 | 6.0 | 18 | 3 | 250,713 | 1,517,515 |
| 2023-03-01 | 0.92 | 23 | 25 | 786,267 | 188,585 |
| 2022-12-01 | 1.5 | 3 | 2 | 24,888 | 1,552,204 |
| 2022-09-01 | 0.875 | 14 | 16 | 165,452 | 3,177,853 |
| 2022-06-01 | 11.0 | 22 | 2 | 309,214 | 12,000 |
| 2022-03-01 | 2.3077 | 30 | 13 | 1,290,339 | 223,173 |
| 2021-12-01 | 0.6667 | 6 | 9 | 200,833 | 218,810 |
| 2021-09-01 | 0.65 | 13 | 20 | 4,234,284 | 4,539,208 |
| 2021-06-01 | 5.0 | 10 | 2 | 243,750 | 2,936,250 |
| 2021-03-01 | 1.2941 | 22 | 17 | 1,209,028 | 102,870 |
| 2020-09-01 | 1.5 | 6 | 4 | 154,863 | 50,000 |
| 2020-06-01 | 0.8889 | 8 | 9 | 1,149,750 | 99,800 |
| 2020-03-01 | 1.7333 | 26 | 15 | 907,208 | 162,762 |
| 2019-06-01 | 0.85 | 17 | 20 | 494,222 | 492,174 |
| 2019-03-01 | 0.9143 | 32 | 35 | 1,416,088 | 689,209 |
| 2018-12-01 | 0.5 | 1 | 2 | 15,000 | 17,000 |
| 2018-06-01 | 1.0 | 13 | 13 | 386,350 | 425,417 |
| 2018-03-01 | 0.75 | 36 | 48 | 2,377,490 | 688,915 |
| 2017-12-01 | 0.6667 | 2 | 3 | 12,500 | 20,000 |
| 2017-03-01 | 1.8 | 18 | 10 | 895,510 | 130,990 |
| 2015-09-01 | 3.0 | 3 | 1 | 46,501 | 1,000.00 |
| 2015-03-01 | 3.0 | 6 | 2 | 523,000 | 2,000 |
| 2014-03-01 | 11.0 | 11 | 1 | 4,045,000 | 0.00 |
| 2013-09-01 | 0.2857 | 2 | 7 | 170,000 | 277,500 |
| 2013-06-01 | 10.0 | 10 | 1 | 1,742,500 | 0.00 |
| 2013-03-01 | 0.3333 | 2 | 6 | 350,000 | 804,672 |
| 2012-12-01 | 0.3846 | 5 | 13 | 140,936 | 6,195,592 |
| 2012-09-01 | 0.3333 | 2 | 6 | 318,750 | 61,500 |
| 2012-06-01 | 1.1429 | 8 | 7 | 165,780 | 132,832 |
| 2012-03-01 | 2.6667 | 24 | 9 | 2,822,846 | 506,181 |
| 2011-12-01 | 2.0 | 4 | 2 | 370,000 | 44,016 |
| 2011-09-01 | 8.0 | 8 | 1 | 49,008 | 584,323 |
| 2010-12-01 | 3.0 | 3 | 1 | 250,000 | 0.00 |
| 2010-06-01 | 7.5 | 15 | 2 | 19,629,130 | 2,566,400 |
| 2010-03-01 | 5.0 | 5 | 1 | 400,000 | 300,000 |
| 2009-12-01 | 1.0 | 2 | 2 | 40,000 | 1,283,200 |
| 2009-06-01 | 1.0 | 7 | 7 | 70,000 | 105,000 |
| 2009-03-01 | 1.0 | 2 | 2 | 105,000 | 62,500 |
| 2008-12-01 | 0.0435 | 1 | 23 | 60,000 | 4,773,168 |
| 2008-03-01 | 4.0 | 4 | 1 | 500,000 | 0.00 |
| 2007-12-01 | 1.1429 | 8 | 7 | 2,300,270 | 78,099 |
| 2007-09-01 | 4.0 | 4 | 1 | 1,250,000 | 1,900 |
| 2007-06-01 | 2.0 | 6 | 3 | 52,500 | 30,000 |
| 2007-03-01 | 0.3636 | 4 | 11 | 135,000 | 138,000 |
| 2006-12-01 | 0.3846 | 5 | 13 | 970,000 | 165,000 |
| 2006-09-01 | 1.0 | 1 | 1 | 20,000 | 0.00 |
| 2006-03-01 | 19.0 | 38 | 2 | 700,029 | 28,000 |
| 2005-12-01 | 2.0 | 2 | 1 | 21,000 | 4,000 |
| 2005-09-01 | 0.3333 | 1 | 3 | 20,000 | 91,000 |
| 2005-06-01 | 4.0 | 4 | 1 | 80,000 | 6,000 |
| 2005-03-01 | 1.2 | 6 | 5 | 348,854 | 101,472 |
| 2004-03-01 | 0.7778 | 7 | 9 | 2,369,972 | 2,248,605 |
Dynavax Technologies Notable Stakeholders
A Dynavax Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dynavax Technologies often face trade-offs trying to please all of them. Dynavax Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dynavax Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Riccardo Manetti | Business President | Profile | |
| Robert Janssen | Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | Profile | |
| Ryan Spencer | Interim Co-President Co-Principal Executive Officer | Profile | |
| Michael Ostrach | Principal Financial Officer, Vice President General Counsel, Chief Business Officer | Profile | |
| Kelly MacDonald | Senior CFO | Profile | |
| David Novack | Sr. VP of Operations and Quality | Profile | |
| Eric Frings | Site VP | Profile | |
| Paul Cox | VP Communications | Profile | |
| Kelly CPA | Principal VP | Profile | |
| Robert MD | Medical Development | Profile | |
| Donn Casale | Senior Officer | Profile | |
| Nicole Arndt | Sr Relations | Profile | |
| Dong Yu | Senior Research | Profile | |
| John Slebir | Senior Counsel | Profile | |
| Jeff Coon | CHRO Administration | Profile | |
| Justin Burgess | Principal Controller | Profile | |
| Meg Smith | VP Operations | Profile | |
| Todd Lopeman | Senior Operations | Profile |
About Dynavax Technologies Management Performance
The success or failure of an entity such as Dynavax Technologies often depends on how effective the management is. Dynavax Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Dynavax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Dynavax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
Please note, the imprecision that can be found in Dynavax Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dynavax Technologies. Check Dynavax Technologies' Beneish M Score to see the likelihood of Dynavax Technologies' management manipulating its earnings.
Dynavax Technologies Workforce Analysis
Traditionally, organizations such as Dynavax Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dynavax Technologies within its industry.Dynavax Technologies Manpower Efficiency
Return on Dynavax Technologies Manpower
| Revenue Per Employee | 684.6K | |
| Revenue Per Executive | 15.4M | |
| Net Income Per Employee | 67.4K | |
| Net Income Per Executive | 1.5M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 42.8M |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.